Background: Amlodipine decreases myocardial oxygen consumption (MVO2) via R+ enantiomer mediated endothelial nitric oxide (NO) release. We investigated the role of angiotensin (AT) 2 and 4 receptors in mediating this effect. Methods: We measured MVO2 in vitro using the Clark type oxygen electrode in isolated LV myocardial segments obtained from (i) wild-type and AT2 receptor knock-out (KD) mice (n=5), and (ii) explanted failing human hearts obtained at the time of heart transplantation (n=2). We studied the effect of increasing doses of R+ enantiomer (10-7M -10-5 M) on MVO2 with and without (i) NO synthase inhibitor, nitro-L-arginine methyl ester (L-NAME, 10-3 M), (ii) AT2 receptor blocker, PD 123319, 10-6-10-5M, and (iii) specific AT4 receptor blocker, divalyl angiotensin 4,10-5M.
Background: ACE inhibitors are well established in the prevention of hypertensionassociated complications of the metabolic syndrome. This study was performed in order to assess the effects of the ACE inhibitor captopril and of the angiotensin II receptor antagonist irbesartan on other conditions of the metabolic syndrome in an animal model.
Methods:
Male NZO/BL6 F1 mice were treated with captopril, irbesartan, or placebo for ten months. Treatment with captopril and irbesartan in equivalent dosage was controlled by monitoring the blood pressure (BP). At the end of the study, gain of body weight (BW), serum levels of insulin, cholesterol, triglycerides and creatinine, cardiac weight and degree of atherosclerosis were determined.
Results:
Control animals treated with placebo developed a metabolic syndrome with obesity (55.5 + 6.3 g), hypertension (t46 + 10 mmHg), hyperinsulinemia (7.2 + 5.7 ng/ ml), hypercholesterolemia (5.1 + 0.7 mmoVI), cardiac hypertrophy (269 + 44 mg) and atherosclerotic plaques in the ascending aorta (3.6 + 1.5 p.rr~). Treatment with ACE inhibitor or angiotensin II receptor antagonist significantly (p<0.001) reduces hypertension (73 + 5 and 78 + 11 mmHg), cardiac hypertrophy (203 + 26 and 202 + 18 mg) and atherosclerosis (2.2 _+ 0.9 and 1.8 _+ 0.8 Hm2). In addition captopril and irbesartan prevented the development of obesity (42.2 + 3.5 and 38.3 ± 2.8 g) and hyperinsulinemia (3.6 ± 1.5 and 1.8 ± 0.4 ng/ml), Irbesartan being somewhat more effective than captopril in the prevention of hyperinsulinemia (p<0.01).
Conclualon:
In a mouse model of the obesity associated metabolic syndrome, long term treatment with an ACE inhibitor or an angiotensin II receptor antagonist, can ameliorate obesity and hypednsufinemia. BACKGROUND: Recent studies have reported that preservation of renal function is an important predictor of survival in congestive heart failure (CHF). A hallmark of overt CHF is an attenuated renal cGMP production to endogenous natriuretic peptides (NPs) and nitdc oxide (NO), which may lead to decline in renal function. Studies have also shown that Angiotensin II (ANG II) activates cGMP phosphodiesterase resulting in increased cGMP degradation. We therefore hypothesized that chronic AT1 receptor antagonism would restore the renal cGMP production in response to endogenous NPs and NO as assessed by urinary cGMP with improved sodium excretion.
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METHODS:
We determined the cardiorenal actions of chronic AT1 blockade (Valsartan, Novartis, 320 mg daily for 10 days, n=5) in a canine model rapid ventricular pacing induced overt CHF (245 bpm for 10 days) as compared to a non-treated group (n=5).
RESULTS:
After 10 days of chronic AT1 receptor antagonism, urinary sodium excretion increased (12.4 ± 3.3 vs 2.7 ± 1.3 uEq/min,p<0.05) in association with a marked increase in urinary cGMP excretion (1558 ± 200 vs 139 ±65 pmol/min, p<0.05) as compared to the non-treated group. The natriuretic response to chronic AT1 receptor antagonism was localized to the inner medullary collecting duct by the lithium clearance technique, a nephron site rich in NPs receptors and sensitive to NO, as distal tubular fractional sodium reabsorption decreased in the AT1 blocker group vs non-treated group (97.6 ± 0.3 vs 98.9 ± 0.5 %, p<O.05). These renal responses where selective as they occurred in the absence of any changes in plasma NPs or cGMP. Chronic AT1 receptor antagonism also reduced cardiac filling pressures consistent with cardiac unloading.
CONCLUSION:
We conclude that chronic AT1 receptor antagonism in experimental overt CHF enhances renal cGMP production, the common secondary messenger for the NPs and NO system resulting in improved renal tubular function and sodium excretion. This study provides insight into renal and humoral pathophysiological actions of ANG II and the AT1 receptor in CHF and mechanisms by which AT1 receptor antagonism may mediate beneficial therapeutic properties by targeting the kidney in this disease state.
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